Kindick (688670.SH) released its 2023 annual performance forecast, which is expected to generate revenue for the full year of 2023...
According to the Zhitong Finance App, Jindick (688670.SH) released the 2023 annual performance forecast. The estimated revenue for the full year of 2023 is 140 million yuan, a decrease of 56.04% over the previous year. It is expected to achieve a net loss of 65 million yuan attributable to the owners of the parent company in 2023. It is estimated that the net loss attributable to the owners of the parent company after deducting non-recurring profit and loss for the year 2023 is 74 million yuan.
The company said that in July 2023, due to sudden heavy rain in the Taizhou area where the company is located, the company's influenza vaccine workshop experienced water seeping. Continuous monitoring of the workshop environment showed that there was a risk of abnormal production environment. The company decided to temporarily stop production at the influenza vaccine workshop due to the principle of prudence. The company only resumed influenza vaccine sales until December 18, 2023, when the company obtained a batch issuance certificate, and the peak sales period for the 2023-2024 influenza season has passed, causing the company's revenue to drop sharply in the second half of the year.